Omicron’s Negative Markets Impact Has Been Dismissed Too Quickly
Technicians work inside a biosafety level 3 Covid-19 research laboratory at the African Health Research Institute (AHRI) in Durban, South Africa, on Dec. 15.
Photographer: Waldo Swiegers/BloombergThis article is for subscribers only.
The concepts of percentages and lagged data series are leading investors toward a complacent conclusion on omicron that doesn’t yet appear justified by empirical data.
There’s a struggle to separate assessments of the individual health threat of the omicron variant from the societal impact. And understandably so, as the related news flow has been non-stop and highly confusing.